Gilead’s Positive Results, Novo Nordisk’s New Insulin Data: Healthcare Business Recap

Gilead Sciences (NASDAQ:GILD) has announced positive results from the first in a series of late-stage evaluations to support the regulatory approval of its hepatitis C pill sofosbuvir, which, if okayed, will comprise the primary component of the first all-oral combination regimen to treat hepatitis C, obviating the need for traditional injectable drugs. The firm anticipates that it will try for approval of the drug in middle of 2013.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

On Tuesday, the Denmark-based insulin maker Novo Nordisk (NYSE:NVO) reported that new data indicated a benefit for type two diabetes patients who were given its diabetes drug Victoza compared with rival drugs from Merck & Co. (NYSE:MRK) and Amylin Pharmaceuticals (NASDAQ:AMLN). In a statement, Novo said that two diabetes patients given Victoza achieved an average blood sugar level below seven percent versus those given Merck’s sitagliptin (Januvia) or Amylin’s exenatid BID.

Don’t Miss: Will This Purchase Boost Sales for GlaxoSmithKline?